Delayed
Japan Exchange
10:27:35 2024-07-07 pm EDT
5-day change
1st Jan Change
911
JPY
-0.87%
-0.98%
+13.88%
AFC-HD AMS Life Science Co., Ltd.'s Equity Buyback announced on May 26, 2023, has closed with 100,000 shares, representing 0.71% for ¥79.57 million.
The company closed its plan on June 27, 2023.
Afc-Hd Ams Life Science Co., Ltd. Announces Dividend for the Second Quarter Ended February 2024, Payable on May 17, 2024
Apr. 15
CI
Afc-Hd Ams Life Science Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending February 2024 and Full Year Ending August 2024
23-10-13
CI
Afc-Hd Ams Life Science Co., Ltd. Announces Dividend for Year Ended August 2023, Payable on November 29, 2023; Provides Dividend Guidance for Year Ending August 2024
23-10-13
CI
AFC-HD AMS Life Science Co., Ltd. agreed to acquire Clarize Co., Ltd. from Toshiaki Fujita for ¥1
23-10-01
CI
AFC-HD AMS Life Science Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending August 31, 2023
23-07-14
CI
AFC-HD AMS Life Science Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending August 31, 2023
23-07-14
CI
Tranche Update on AFC-HD AMS Life Science Co., Ltd.'s Equity Buyback Plan announced on May 26, 2023.
23-06-27
CI
AFC-HD AMS Life Science Co., Ltd.'s Equity Buyback announced on May 26, 2023, has closed with 100,000 shares, representing 0.71% for ¥79.57 million.
23-06-26
CI
AFC-HD AMS Life Science Co., Ltd. announces an Equity Buyback for 100,000 shares, representing 0.71% for ¥100 million.
23-05-26
CI
AFC-HD AMS Life Science Co., Ltd. authorizes a Buyback Plan.
23-05-25
CI
AFC-HD AMS Life Science Co., Ltd. Announces Dividend for the Second Quarter Ended Feb. 2023, Payable on May 29, 2023
23-04-14
CI
AFC-HD AMS Life Science Co., Ltd. Provides Earnings Guidance for the Year Ending August 2023
23-04-14
CI
AFC-HD AMS Life Science Co., Ltd. Provides Dividend Guidance for the Year Ending August 2023
23-04-14
CI
AFC-HD AMS Life Science Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal 2023
23-01-13
CI
AFC-HD AMS Life Science Co., Ltd. Provides Consolidated Earnings Guidance for the Period Ending February 2023 and August 2023
23-01-13
CI
AFC-HD AMS Life Science Co., Ltd. agreed to acquire a 51% stake in 5SPRO Joint Stock Company.
22-12-11
CI
AFC-HD AMS Life Science Co., Ltd. Provides Consolidated Earnings Guidance for the Period Ending February 2023 and August 2023
22-10-14
CI
AFC-HD AMS Life Science Co., Ltd. Provides Dividend Guidance for the Second Quarter and Year End of Fiscal 2023
22-10-14
CI
AFC-HD AMS Life Science Co., Ltd. Announces Dividend for the Year End August 2022, Payable on November 30, 2022
22-10-14
CI
AFC-HD AMS Life Science Co., Ltd. Provides Consolidated Earnings Guidance for the Period Ending August 31, 2022
22-07-15
CI
AFC-HD AMS Life Science Co., Ltd. Provides Earnings Guidance for the Period Ending August 2022
22-04-14
CI
AFC-HD AMS Life Science Co., Ltd. Announces Dividend for the Second Quarter of 2022, Payable on May 16, 2022
22-04-14
CI
AFC-HD AMS Life Science Co., Ltd. Provides Dividend Guidance for the Year End August 2022
22-04-14
CI
AFC-HD AMS Life Science Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending August 2022
22-01-14
CI
AFC-HD AMS Life Science Co., Ltd. Provides Dividend Guidance for the Second Quarter of the Year Ending August 31, 2022
22-01-14
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
AFC-HD AMS Life Science Co Ltd is a Japan-based company mainly engaged in the development of the healthcare business and the pharmaceutical business. The Company is engaged in the research and development, product design, manufacture and sale of health foods and cosmetics, manufacture and sale of Chinese medicine medicines, general medicines, generic medicines, healthcare products, the sale of natural foods, as well as planning of health information programs. The Company operates in two business segments. The Healthcare segment is engaged in the manufacture and sale of health foods and cosmetics, as well as the provision of original equipment manufacturers (OEM). The Pharmaceutical segment is engaged in the manufacture and sale of ethical drugs and over-the-counter drugs, as well as the sale of generic drugs. The Company is also engaged in the management of restaurants through subsidiary.
More about the company
1st Jan change
Capi.
+13.88% 79.91M +13.33% 8.13B +9.35% 7.91B -19.26% 4.76B -8.54% 3.63B -20.61% 3.16B -12.55% 1.2B -26.47% 1.12B -7.63% 892M -17.95% 838M
Special Foods & Wellbeing Products
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1